Effect of sucralfate on gastric mucosal inflammatory responses induced by Helicobacter pylori lipopolysaccharide. 1998

B L Slomiany, and J Piotrowski, and A Slomiany
Research Center, University of Medicine and Dentistry of New Jersey, Newark, USA.

BACKGROUND Helicobacter pylori lipopolysaccharide is emerging as a primary factor in the bacterium virulence, and its involvement in causing gastric mucosal responses typical of gastritis has recently been shown. In this study we investigated the effect of the antiulcer agent sucralfate on the expression of regulatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-4 (IL-4), and epithelial cell apoptosis during H. pylori lipopolysaccharide-induced acute gastritis. METHODS The experiments were conducted with rats pretreated intragastrically twice daily for 3 days with sucralfate at 100 mg/kg or the vehicle. The rats were then subjected to intragastric surface epithelial application of H. pylori lipopolysaccharide at 50 microg per animal and maintained on the sucralfate or vehicle regimen for an additional 4 days. The animals were killed 16 h after the last dose, and their gastric mucosal tissue used for histologic assessment, quantitation of TNF-alpha and IL-4 expression, and the assay of epithelial cell apoptosis. RESULTS In the absence of sucralfate, H. pylori lipopolysaccharide induced acute mucosal responses characterized by the inflammatory infiltration of the lamina propria, hyperemia, and epithelial hemorrhage. This was accompanied by an 11-fold increase in gastric epithelial cell apoptosis and a 9-fold enhancement of the mucosal expression of TNF-alpha, but the level of IL-4 fell by 15%. Intragastric administration of sucralfate produced a 62% reduction in the extent of mucosal damage caused by H. pylori lipopolysaccharide, a 51% decrease in the mucosal expression of TNF-alpha, and a 7-fold reduction in the extent of epithelial cell apoptosis, whereas the expression of IL-4 increased by 52%. CONCLUSIONS Gastric mucosal inflammatory responses to H. pylori lipopolysaccharide are characterized by a massive enhancement of the proinflammatory cytokine TNF-alpha and epithelial cell apoptosis and repression of IL-4. Our data also show that sucralfate is capable of inducing expression of the regulatory cytokine IL-4 and the suppression of apoptotic events triggered in gastric mucosa by the increase in TNF-alpha that is elicited by H. pylori lipopolysaccharide.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D005756 Gastritis Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders. Gastritides
D006471 Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Hematochezia,Hemorrhage, Gastrointestinal,Gastrointestinal Hemorrhages,Hematochezias
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer
D013392 Sucralfate A basic aluminum complex of sulfated sucrose. Aluminum Sucrose Sulfate,Antepsin,Basic Aluminum Sucrose Sulfate,Carafate,Ulcerban,Ulcogant,Ulsanic,Sulfate, Aluminum Sucrose
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015847 Interleukin-4 A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. B-Cell Growth Factor-I,B-Cell Stimulatory Factor-1,Binetrakin,IL-4,Mast Cell Growth Factor-2,B Cell Stimulatory Factor-1,B-Cell Growth Factor-1,B-Cell Proliferating Factor,B-Cell Stimulating Factor-1,B-Cell Stimulatory Factor 1,BCGF-1,BSF-1,IL4,MCGF-2,B Cell Growth Factor 1,B Cell Growth Factor I,B Cell Proliferating Factor,B Cell Stimulating Factor 1,B Cell Stimulatory Factor 1,Interleukin 4,Mast Cell Growth Factor 2
D016480 Helicobacter pylori A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405). Campylobacter pylori,Campylobacter pylori subsp. pylori,Campylobacter pyloridis,Helicobacter nemestrinae

Related Publications

B L Slomiany, and J Piotrowski, and A Slomiany
June 2003, Biochemical and biophysical research communications,
B L Slomiany, and J Piotrowski, and A Slomiany
April 1996, Alimentary pharmacology & therapeutics,
B L Slomiany, and J Piotrowski, and A Slomiany
November 2005, Biochemical and biophysical research communications,
B L Slomiany, and J Piotrowski, and A Slomiany
April 1992, Alimentary pharmacology & therapeutics,
B L Slomiany, and J Piotrowski, and A Slomiany
April 2019, Inflammopharmacology,
B L Slomiany, and J Piotrowski, and A Slomiany
February 2002, Nihon rinsho. Japanese journal of clinical medicine,
B L Slomiany, and J Piotrowski, and A Slomiany
December 2002, The Keio journal of medicine,
B L Slomiany, and J Piotrowski, and A Slomiany
February 2002, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!